Cargando…
Medical Management of Hereditary Optic Neuropathies
Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117178/ https://www.ncbi.nlm.nih.gov/pubmed/25132831 http://dx.doi.org/10.3389/fneur.2014.00141 |
_version_ | 1782328678694256640 |
---|---|
author | La Morgia, Chiara Carbonelli, Michele Barboni, Piero Sadun, Alfredo Arrigo Carelli, Valerio |
author_facet | La Morgia, Chiara Carbonelli, Michele Barboni, Piero Sadun, Alfredo Arrigo Carelli, Valerio |
author_sort | La Morgia, Chiara |
collection | PubMed |
description | Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads to the selective loss of retinal ganglion cells and axons, in particular of the papillo-macular bundle. Typically, LHON is characterized by an acute/subacute loss of central vision associated with impairment of color vision and swelling of retinal nerve fibers followed by optic atrophy. DOA, instead, is characterized by a childhood-onset and slowly progressive loss of central vision, worsening over the years, leading to optic atrophy. The diagnostic workup includes neuro-ophthalmologic evaluation and genetic testing of the three most common mitochondrial DNA mutations affecting complex I (11778/ND4, 3460/ND1, and 14484/ND6) for LHON and sequencing of the nuclear gene OPA1 for DOA. Therapeutic strategies are still limited including agents that bypass the complex I defect and exert an antioxidant effect (idebenone). Further strategies are aimed at stimulating compensatory mitochondrial biogenesis. Gene therapy is also a promising avenue that still needs to be validated. |
format | Online Article Text |
id | pubmed-4117178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-41171782014-08-15 Medical Management of Hereditary Optic Neuropathies La Morgia, Chiara Carbonelli, Michele Barboni, Piero Sadun, Alfredo Arrigo Carelli, Valerio Front Neurol Neuroscience Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads to the selective loss of retinal ganglion cells and axons, in particular of the papillo-macular bundle. Typically, LHON is characterized by an acute/subacute loss of central vision associated with impairment of color vision and swelling of retinal nerve fibers followed by optic atrophy. DOA, instead, is characterized by a childhood-onset and slowly progressive loss of central vision, worsening over the years, leading to optic atrophy. The diagnostic workup includes neuro-ophthalmologic evaluation and genetic testing of the three most common mitochondrial DNA mutations affecting complex I (11778/ND4, 3460/ND1, and 14484/ND6) for LHON and sequencing of the nuclear gene OPA1 for DOA. Therapeutic strategies are still limited including agents that bypass the complex I defect and exert an antioxidant effect (idebenone). Further strategies are aimed at stimulating compensatory mitochondrial biogenesis. Gene therapy is also a promising avenue that still needs to be validated. Frontiers Media S.A. 2014-07-31 /pmc/articles/PMC4117178/ /pubmed/25132831 http://dx.doi.org/10.3389/fneur.2014.00141 Text en Copyright © 2014 La Morgia, Carbonelli, Barboni, Sadun and Carelli. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience La Morgia, Chiara Carbonelli, Michele Barboni, Piero Sadun, Alfredo Arrigo Carelli, Valerio Medical Management of Hereditary Optic Neuropathies |
title | Medical Management of Hereditary Optic Neuropathies |
title_full | Medical Management of Hereditary Optic Neuropathies |
title_fullStr | Medical Management of Hereditary Optic Neuropathies |
title_full_unstemmed | Medical Management of Hereditary Optic Neuropathies |
title_short | Medical Management of Hereditary Optic Neuropathies |
title_sort | medical management of hereditary optic neuropathies |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117178/ https://www.ncbi.nlm.nih.gov/pubmed/25132831 http://dx.doi.org/10.3389/fneur.2014.00141 |
work_keys_str_mv | AT lamorgiachiara medicalmanagementofhereditaryopticneuropathies AT carbonellimichele medicalmanagementofhereditaryopticneuropathies AT barbonipiero medicalmanagementofhereditaryopticneuropathies AT sadunalfredoarrigo medicalmanagementofhereditaryopticneuropathies AT carellivalerio medicalmanagementofhereditaryopticneuropathies |